Abemaciclib, a CDK4 & 6 inhibitor, has shown a sustained benefit in invasive disease-free survival in high-risk EBC, as seen in the monarchE trial. While effective, abemaciclib does have side effects, and these can be more pronounced in older patients. Diarrhea, fatigue, and neutropenia are among the common adverse events. Older patients require careful monitoring. … Continue reading Abemaciclib in Focus: A Look at monarchE Trial